Table 3.
Comparison of Varenicline Adverse Events and Effectiveness Rates % (95% CI) Between the Current and Previously Published Studies
| Study | Total n | Any AE | Nausea | Abnormal dreams | Discontinuation | 4W-CAR weeks 9–12 | CAR weeks 9–24 |
|---|---|---|---|---|---|---|---|
| Current study | 36 | 78 (64, 91) | 33 (18, 49) | 31 (16, 46) | 28 (13, 42) | 42 (26, 58) | 28 (13, 42) |
| Wang et al., 200928 | 165 | 77 (71, 83) | 29 (22, 36) | 4 (1, 7) | 3 (0, 6) | 50 (42, 58) | 38 (31, 46) |
| Aubin et al., 200829 | 376 | 85 (81, 88) | 37 (32, 42) | 12 (8, 15) | 17 (13, 21) | 56 (51, 61) | 32 (28, 37) |
| Nakamura et al., 200730 | 156 | 80 (74, 86) | 24 (18, 31) | — | 8 (4, 13) | 65 (57, 74) | 38 (29, 46) |
| Tsai et al., 200731 | 126 | 87 (81, 92) | 44 (35, 52) | 6 (2, 10) | — | 60 (51, 68) | 47 (38, 56) |
| Oncken et al., 200632 | 130 | 79 (72, 86) | 35 (27, 43) | 19 (13, 26) | 23 (16, 31) | 55 (46, 63) | — |
| Jorenby et al., 200633 | 344 | — | 29 (25, 34) | 13 (10, 17) | 24 (20, 29) | 44 (39, 49) | 30 (25, 34) |
| Gonzales et al., 200634 | 352 | 79 (75, 83) | 28 (23, 33) | 10 (7, 14) | 26 (21, 30) | 44 (39, 49) | 30 (25, 34) |
| Pooled studya | 82 (80, 84) | 32 (29, 34) | 9 (8, 11) | 13 (11, 14) | 51 (49, 54) | 33 (31, 36) | |
| p value | 0.545 | 0.819 | <0.001 | 0.011 | 0.248 | 0.495 |
a
Pooled study: studies 28–34, all of them were conducted in non-HIV generally healthy smokers, and only the arm using varenicline 1.0 mg twice daily for 12 weeks was included. Estimations in pooled study were weighted by the variance in each study. p values were calculated by one sample t-test, where the proportions in our study were compared to that in pooled study.
AE, adverse event; 4W-CAR, 4-week continuous abstinence rate; CAR, continuous abstinence rate.